Lotus Pharmaceutical Co., Ltd. (TPE: 1795)

Market Cap	73.55B
Revenue (ttm)	16.93B
Net Income (ttm)	4.01B
Shares Out	265.05M
EPS (ttm)	15.27
PE Ratio	18.17
Forward PE	14.46
Dividend	4.65 (1.72%)
Ex-Dividend Date	Aug 5, 2024

Volume	1,814,581
Open	286.00
Previous Close	284.50
Day's Range	278.50 - 288.00
52-Week Range	205.00 - 347.00
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2023, Lotus Pharmaceutical's revenue was 16.96 billion, an increase of 15.89% compared to the previous year's 14.63 billion. Earnings were 4.11 billion, an increase of 35.91%.